| abstract |
In a method for treating diabetes mellitus, it has a long-term action profile due to a mutation for improving stability against protease degradation, which can be administered pulmonary, orally or intravenously. Provision of new insulin analogues. For human insulin, acylated protease stability in which at least one hydrophobic amino acid is substituted with a hydrophilic amino acid and one or more acyl moieties are bound to the N-terminal position or lysine residue. Insulin. [Selection] Figure 1 |